In this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
Michael W. Magdycz
Advertisement
Articles by Michael W. Magdycz
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
2
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
3
Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive
4
New FDA Draft Guidance Targets Gene Therapy Submission Burden by Allowing Use of Existing CMC and Scientific Knowledge
5